{"id":"shr-a2102-for-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, SHR-A2102 for Injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby promoting an anti-tumor immune response. This mechanism is thought to enhance the body's ability to recognize and attack cancer cells. The exact molecular details of this interaction are complex and involve multiple protein domains.","oneSentence":"SHR-A2102 for Injection is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:28.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07418749","phase":"PHASE3","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":398},{"nctId":"NCT06512051","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-07-30","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":248},{"nctId":"NCT07175220","phase":"PHASE2","title":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-09","conditions":"Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT06738251","phase":"PHASE3","title":"A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-02-12","conditions":"Advanced Urothelial Carcinoma","enrollment":402},{"nctId":"NCT06819319","phase":"PHASE2","title":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-06-23","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":52},{"nctId":"NCT06879145","phase":"PHASE2, PHASE3","title":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-25","conditions":"Muscular Invasive Bladder Cancer (MIBC)","enrollment":840},{"nctId":"NCT06895928","phase":"PHASE2","title":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-03-28","conditions":"Advanced Solid Tumors","enrollment":400},{"nctId":"NCT06474468","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Advanced or Metastatic Esophageal Cancer","enrollment":148},{"nctId":"NCT06417554","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-05-13","conditions":"Advanced Solid Tumors","enrollment":80},{"nctId":"NCT06654440","phase":"PHASE2","title":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-15","conditions":"Advanced Gynecological Malignancy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-A2102 for Injection","genericName":"SHR-A2102 for Injection","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A2102 for Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}